Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea's Celltrion Cuts Deal With Jordan-Based Hikma To Sell Its Biosimilars In The Middle East, Africa

This article was originally published in The Pink Sheet Daily

Executive Summary

Celltrion has been developing nine blockbuster biosimilar therapeutic antibodies in line with a bid to launch three in markets not protected with patent rights. The firm is moving to globally launch the biosimilars around 2011.

You may also be interested in...

Korea's Celltrion Cuts Deal With Perrigo To Sell Its Biosimilars In Israel

SEOUL - As part of its bid to stretch out for more global sales for a range of antibody therapeutic biosimilars, Celltrion has signed a deal with Perrigo to market its products in Israel

Korea's Celltrion Gains Foothold in Europe; Wins Clinical Trial Approval from Latvia For Herceptin Biosimilar

SEOUL - South Korea's Celltrion has secured an approval from EU member Latvia to perform clinical trials for its Herceptin (trastuzumab) biosimilar as part of its effort to prepare for the expiration of Roche's patent rights on the product in 2019 in Europe and the U.S

Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions

SEOUL - "Celltrion is currently developing a total of nine blockbuster antibody therapeutic biosimilars, and we are preparing for the launch of three biosimilars for markets not protected with patent rights," Kim Yong-Joong, Celltrion's strategic planning assistant manager, told PharmAsia News


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts